Vered Stearns, M.D.
![](https://images.med.cornell.edu/headshots/ves4007.jpg?b5f691b991)
Locations and Appointments
Please contact the doctor's office to verify that your insurance is accepted.
*Indicates this doctor is no longer accepting new patients with this insurance plan.
- HMO
- Medicare
- PPO
- EPO/POS
- Blue Access
- EPO
- HMO
- PPO
- CBP
- Medicaid
- Medicare
- Freedom
- Liberty
- Medicare Advantage
- Metro/Core/Charter
- Community Plan
- Medicare
- HMO
- Medicare
About Vered Stearns, M.D.
I became interested in oncology before I even knew the meaning of the word. My grandfather died of cancer when I was just 5 years-old, and that was a turning point for me in which I decided that when I grew up, I wanted to become a doctor and cure cancer. While my understanding of oncology has since become more sophisticated, it’s important to me that I never lose my childhood enthusiasm for improving the welfare and wellbeing of those impacted by cancer. During my Hematology and Medical Oncology Fellowship, I first began to focus on breast cancer, and enjoyed the privilege of working with internationally recognized physician-scientists who were able to make an impact in both the laboratory and the clinic. This inspired me to want to continue to work to translate state-of-the-art research into the context of patient treatments and care. My long-term research goal is to improve current therapies by individualizing strategies for the treatment and prevention of breast cancer. My main investigations focus on biomarkers that may predict response to standard regimens used to treat and prevent breast cancer and to introduce new approaches. I have also conducted translational studies designed to improve wellness of those living with and beyond breast cancer.
Dr. Vered Stearns completed the equivalent of a B.S. degree at the Tel Aviv University, Sackler Faculty of Medicine in 1989. After relocating to the United States, Dr. Stearns transferred to and graduated from the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School with a medical degree (M.D.) in 1992. She completed a residency in Internal Medicine and a fellowship in Medical Oncology at the Georgetown University where she developed an interest in translational breast cancer research and spent two additional years as a research fellow.
Dr. Stearns was a faculty member at the Lombardi Comprehensive Cancer Center and the Georgetown University, and at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan before joining the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in 2002. She remained at Johns Hopkins and served in a variety of roles, including co-Director of the Breast Cancer Program, co-Director of the Breast and Ovarian Cancer Program, Director, Women’s Malignancies Disease Group and inaugural Medical Director of the Under Armour Breast Health Innovation Center, until being recruited to Weill Cornell Medicine and New York-Presbyterian Hospital in 2023. At Weill Cornell Medicine, Dr. Stearns is Director of Translational Breast Cancer Research at the Department of Medicine, and Associate Director for Clinical Services at the Meyer Cancer Center. Her role in the Meyer Cancer Center will allow her to develop programs and to mentor team members across diseases throughout Manhattan, Brooklyn and Queens.
Dr. Stearns’s long-term research goal is to improve current therapies by individualizing strategies for the treatment and prevention of breast cancer. The main focus of Dr. Stearns’s research includes the utilization of biomarkers to predict response to standard regimens used to treat and prevent breast cancer, and to introduce new interventions.
Dr. Stearns and colleagues from the Consortium On Breast Cancer Pharamcogenomics (COBRA) Group were the first to evaluate the role of genetic variants in candidate genes such as CYP2D6 in tamoxifen metabolism, safety, and efficacy. This work has been extended to evaluate the role of genetic variants in aromatase inhibitor associated outcomes. She has also conducted clinical investigations of epigenetic modifying agents across the breast cancer continuum. She is evaluating whether histone deacetylase inhibitors enhance response to immunotherapy. Having demonstrated that methylation markers predict breast cancer risk, she is evaluating whether natural compounds can reverse these modifications.
Dr. Stearns has received numerous grants and awards to fund her innovative research. She was a recipient of early career awards including a Clinical Research Training Grant from the American Cancer Society, and was one of the first five recipients of the prestigious Damon Runyon Clinical Investigator Award. Subsequently she was the inaugural recipient of the American Society of Clinical Oncology (ASCO) Advanced Clinical Research Award.
She served as a Board Member of the National Accreditation Program for Breast Centers (NAPBC) for the American College of Surgeons (ACS), and was elected in 2020 as Fellow of the American Society of Clinical Oncology (FASCO). Her work has already had a positive impact on the lives of many women, and in 2017, Dr. Stearns was selected by Forbes as one of 27 top breast cancer oncologists in the United States. Dr. Stearns is Vice Chair of the NRG Translational Science Committee, and Co-Chair of the NRG Breast Translational Working Group. In these roles, she works closely with Group members as they investigate correlative biomarkers obtained through breast cancer trials.
-
M.D.University of Medicine and Dentistry of New Jersey1992
-
Attending PhysicianNewYork-Presbyterian Hospital
-
Professor of Medicine (Pending Appointment at Rank)Weill Cornell Medical College, Cornell University
External Relationships
Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.
No External Relationships Reported